Q&A With Sutro's William Newell
Executive Summary
Bill Newell discusses the progress of Sutro’s commercialization programs on ADCs as well as lessons on leading a small biotech in a crowded competitive field of big pharma players.
You may also be interested in...
Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.
Academia Meets The Market – Part Two
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.
Academia Meets The Market – Part One
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside. Its commercial impact is considerable: over the past two decades, private-sector VC’s have invested more than $2bn in UCLA-backed innovations, with 26 start-ups launched through the university in 2019 alone. Amir Naiberg, UCLA’s point man on technology transfer, explains the factors that have made the university a successful advocate for partnerships that produce results for patients.
Need a specific report? 1000+ reports available
Buy Reports